Theranos was founded around the opportunity to integrate existing nano and bio-technologies to more accurately monitor whole blood analytes and determine drug dosing and delivery schemes. By optimizing the power behind cornerstone optical tools and interfacing them in biological systems we are enabling unparalleled sensitivity for therapeutic drug monitoring. As such, we respond to demands posed by the pharmaceutical industry for a novel development infrastructure that will facilitate the progression of highly potent drug candidates through clinical trials and on to market.


Date Type Amount Investors Valuation
11/10/06 Series C 22M ATA Ventures, DFJ Unknown